Abarelix vs Gonadorelin (GnRH)
GnRH Antagonist for Advanced Prostate Cancer Treatment
The master hormone that controls your reproductive system and fertility
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Abarelix
100–100 mg
Gonadorelin (GnRH)
100–100 mcg
Frequency
Abarelix
Once daily
Gonadorelin (GnRH)
Once daily
Administration
Abarelix
Intramuscular injection (depot formulation)
Gonadorelin (GnRH)
Subcutaneous injection
Cycle length
Abarelix
Ongoing/indefinite
Gonadorelin (GnRH)
Ongoing/indefinite
Onset speed
Abarelix
Moderate (1-2 weeks)
Gonadorelin (GnRH)
Moderate (1-2 weeks)
Evidence level
Abarelix
Strong human trials (Phase 3 or FDA approved)
Gonadorelin (GnRH)
Moderate human trials (Phase 1-2)
Benefit ratings
Rapid Hormone Control
Advanced Cancer Management
Patient Tolerability
Reproductive Health
Hormone Balance
Ovulation Support
Compound specifications
Abarelix
Molecular formula
C72H95ClN14O14
Molecular weight
1416.1 g/mol
Half-life
Approximately 13 days
Bioavailability
~100% (intramuscular depot injection)
CAS number
183552-38-7
Gonadorelin (GnRH)
Molecular formula
C55H75N17O13
Molecular weight
1182.3
Half-life
2-4 minutes
Bioavailability
Varies by route: ~5-20% (intranasal), 100% (IV/IM injections)
CAS number
34973-08-5
Dosing compared
Abarelix
Intramuscular
100 mg
Day 1, 15, 29, then every 4 weeks · Up to 12 months (effectiveness beyond 12 months not established)
This is the FDA-approved dose for advanced prostate cancer. A 100 mg shot is given into the buttock muscle on day 1, 15, and 29, then once every 4 weeks. The drug was sold as Plenaxis. [4]
Gonadorelin (GnRH)
Subcutaneous
100 mcg
Single dose · One-time diagnostic test
FDA-labeled gonadotropin (LH/FSH) stimulation test for pituitary reserve; 100 mcg given once subcutaneously (or IV), with LH measured at 0, 15, 30, 45, 60 and 120 minutes (Factrel) [4].
Intravenous
5 mcg per pulse (range 1-20 mcg)
Every 90 minutes via pulsatile pump · One or more ovulatory cycles; reassessed at 21-day intervals
FDA-labeled pulsatile regimen for ovulation induction in hypothalamic amenorrhea (Lutrepulse); intravenous pulsatile delivery gave better results than subcutaneous [5]. The 2-4 minute half-life makes pulsatile delivery essential.
Best suited for
Abarelix
Reducing testosterone levels in prostate cancer
Abarelix is particularly well-suited for individuals focused on reducing testosterone levels in prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Slowing cancer progression in advanced disease
Abarelix is particularly well-suited for individuals focused on slowing cancer progression in advanced disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing hormone-dependent cancer symptoms
Abarelix is particularly well-suited for individuals focused on managing hormone-dependent cancer symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gonadorelin (GnRH)
Improving fertility and conception chances
Gonadorelin (GnRH) is particularly well-suited for individuals focused on improving fertility and conception chances. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Regulating irregular menstrual cycles
Gonadorelin (GnRH) is particularly well-suited for individuals focused on regulating irregular menstrual cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing reproductive hormone levels
Gonadorelin (GnRH) is particularly well-suited for individuals focused on enhancing reproductive hormone levels. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting natural pregnancy attempts
Gonadorelin (GnRH) is particularly well-suited for individuals focused on supporting natural pregnancy attempts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Abarelix
Common
- Mild discomfort at treatment site
- Hot flashes and sweating
- Decreased libido and sexual dysfunction
- Increased liver enzymes
- Injection site reactions (pain, redness, swelling)
- Abdominal pain and gastrointestinal symptoms
- Headache and dizziness
- Weight changes
- Gynecomastia (breast tissue enlargement)
- Bone density loss with long-term use
Serious
- Severe allergic reaction
Gonadorelin (GnRH)
Common
- Mild headache
- Local injection site reactions (redness, swelling)
- Temporary hot flashes
- Mood changes or emotional sensitivity
- Nausea or mild stomach upset
- Allergic skin reactions
- Dizziness or lightheadedness
- Temporary changes in vision
- Joint or muscle aches
- Insomnia or sleep disturbances
- Severe allergic reactions (difficulty breathing, swelling)
- Severe hormonal imbalance symptoms
- Ovarian hyperstimulation syndrome (OHSS)
- Signs of blood clots (chest pain, leg swelling)
- Severe mood changes or depression
Serious
- Severe allergic reaction
Safety & evidence
Abarelix
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for other use
Safety overview
Abarelix carries significant safety concerns primarily related to histamine release reactions, which led to its voluntary withdrawal from the U.S. market in 2006. Serious allergic responses including anaphylaxis, flushing, and hypotension have been documented. Long-term use poses substantial risks of bone density loss, cardiovascular effects from hormonal suppression, and metabolic complications including weight gain and altered lipid profiles. Liver enzyme elevations occur in 5-10% of patients. All use requires intensive medical supervision with regular monitoring of testosterone levels, liver function, bone density, and cardiovascular markers.
Contraindications
- Pregnancy or lactation
- Severe hypersensitivity reactions to peptide therapeutics
- History of anaphylaxis with similar compounds
Gonadorelin (GnRH)
Evidence level
Moderate human trials (Phase 1-2)
FDA status
FDA approved for this use
Safety overview
Gonadorelin is native GnRH and carries the safety profile established over 40+ years of clinical use in reproductive endocrinology. As the body's natural hormone, it produces minimal local side effects when dosed appropriately. The critical safety concern with gonadorelin is the initial flare effect within 24-48 hours of first dose—temporary elevation in FSH and LH—which can paradoxically suppress sex hormones before the desired stimulation occurs. This flare makes gonadorelin unsuitable for some conditions and explains why synthetic analogs (agonists, antagonists) are preferred in many modern fertility protocols.
Contraindications
- Pregnancy or breastfeeding
- Hormone-sensitive cancers (breast, prostate, ovarian)
- Severe pituitary or hypothalamic disease
- Undiagnosed abnormal vaginal bleeding
- Known hypersensitivity to GnRH
Which is right for you?
Choose Abarelix if...
- Reducing testosterone levels in prostate cancer
- Slowing cancer progression in advanced disease
- Managing hormone-dependent cancer symptoms
Choose Gonadorelin (GnRH) if...
- Improving fertility and conception chances
- Regulating irregular menstrual cycles
- Enhancing reproductive hormone levels
- Supporting natural pregnancy attempts